Abstract 378P
Background
Tan Tock Seng Hospital (TTSH) Cancer Genetics and Genomics Clinic (CGGC) was set up by the Personalised Medicine Services (PMS) and Department of Medical Oncology (DMO) in December 2017 to provide genetic counselling service for inherited cancer syndromes diagnosis, risk assessment and treatment recommendation. Patient’s affordability for genetic testing was noted as one of the greatest challenges. In January 2019, a diagnostic access program was established between AstraZeneca Singapore and PMS to reduce cost barriers for patients who fulfil clinical guidelines for BRCA1/2 testing.
Methods
This is a retrospective study of BRCA1/2 test utilisation by patients who were seen at CGGC. The oncologist made the decision on the use of a targeted BRCA1/2 or multi-gene panels for genetic testing. The objectives of this study were to examine the clinical utilisation of BRCA1/2 testing, and to determine the proportion of patients who benefited from the access program.
Results
To date, 101 out of 140 patients were seen at CGGC for BRCA-related testing. Patients’ referral are mainly from DMO and Breast Clinic. With the increased use of PARP inhibitors for germline BRCA-mutated cancers, the number of patients referred to CGGC has increased 20% per month. The percentage of breast, prostate, pancreatic and ovarian cancer patients seen are 75%, 11%, 10% and 5%, respectively. The introduction of the access program has greatly increased the testing rate from 50% to 85%. The positive detection rate was 11%. Among 65 that underwent testing, 7 patients were tested BRCA1/2 mutation positive, which resulted in protein truncation or disruption. However, the take up rate for carrier testing was low, probably due to fear of being affected and insurance discrimination. The variant of unknown significance rate for BRCA1/2 was 14%. Among the 75% tested BRCA1/2 negative, a genetic cause of their cancer cannot be ruled out. For example, 2 BRCA1/2 negative breast cancer patients were tested positive in CHEK2 and PALB2 genes.
Conclusions
CGGC service in TTSH is growing rapidly and has closed an important gap in our patient treatment journey. The sponsorship by AstraZeneca has greatly benefited our patients who might be at risk of inherited cancer syndromes and would potentially benefit from PARP inhibitors treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tan Tock Seng Hospital.
Funding
AstraZeneca Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract